@2024 - All Right Reserved.
Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to ...
Patients with poorly controlled type 2 diabetes despite being on dulaglutide had better outcomes if they switched to tirzepatide than if they upped their dulaglutide dose. In this randomized trial, ...
Mounjaro met the primary objective of non-inferiority vs. Trulicity with an 8% lower rate of MACE-3 events, while delivering greater reductions in A1C and weight In the trial, Mounjaro was associated ...
VIENNA — Tirzepatide (Mounjaro) is cardioprotective in people with type 2 diabetes (T2D) and established atherosclerotic cardiovascular (CV) disease, but not more so than dulaglutide (Trulicity), ...
Please provide your email address to receive an email when new articles are posted on . Risk for major adverse CV events was similar for adults receiving tirzepatide vs. dulaglutide. All-cause ...
Eli Lilly has further expanded its weight-loss initiatives with novel therapies such as orforglipron, an oral GLP-1 receptor ...
Please provide your email address to receive an email when new articles are posted on . Dulaglutide, semaglutide and tirzepatide had similar GI safety profiles. An increased risk for GI adverse events ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results